Development of genetic testing for breast, ovarian and colorectal cancer predisposition: A step closer to targeted cancer prevention

Current Drug Targets

Volumn 12, Issue 13, 2011, Pages 1974-1982

  Eccles, D M ^a  

^a PRINCESS ANNE HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Clinical utility; Colon cancer; Genetic; High risk; Predisposition; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; APC PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA GLYCOSYLASE MUTY; ESTROGEN; FLUOROURACIL; GONADORELIN AGONIST; METHOTREXATE; PLACEBO; PROGESTERONE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P53; RALOXIFENE; STARCH; SULINDAC; TAMOXIFEN;

ALLELE; ARTICLE; BREAST CANCER; BREAST SELF EXAMINATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SURGERY; CANCER SUSCEPTIBILITY; COLON ADENOMA; COLON CANCER; COLON CARCINOMA; COLON RESECTION; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; DESMOID TUMOR; DNA CROSS LINKING; DRUG MEGADOSE; EARLY DIAGNOSIS; ECHOGRAPHY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ENVIRONMENTAL FACTOR; EPIDERMOID CYST; FAMILIAL CANCER; FAMILIAL COLON POLYPOSIS; GARDNER SYNDROME; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LIFESTYLE; MALIGNANT TRANSFORMATION; MAMMOGRAPHY; MASTECTOMY; METASTASIS; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMA; OVARY CANCER; PENETRANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SALPINGOOOPHORECTOMY; SOMATIC MUTATION; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE CYTOLOGY; UROGENITAL TRACT TUMOR;

ALLELES; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; GENERAL SURGERY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; OVARIAN NEOPLASMS; PENETRANCE; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 82055161796     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011798184209     Document Type: Article

References (87)

1. Bodmer WF, Bailey CJ, Bodmer J, et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 1987; 328: 614-6.
2. Kinzler KW, Nilbert MC, Vogelstein B, et al. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 1991; 251: 1366-70.
3. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986; 323: 643-6.
4. Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993; 75: 1215-25.
5. Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75: 1027-38.
6. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250: 1684-9.
7. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
8. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994; 265: 2088-90.
9. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-92.
10. Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2010; 28: 893-901.
11. McIntosh A, Shaw C, Evans G, et al. Clinical guidelines and evidence review for the classification and care of women at risk of familial breast cancer. National Collaborating Centre for Primary Care: 2006; [http://www.nice.org.uk/CG041].
12. Bodmer W, Bonilla C. Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet 2008; 40: 695-701.
13. Pigatto F, Bateman A, Bunyan D, et al. Economic and practical factors in diagnosing HNPCC using clinical criteria, immunohistochemistry and microsatellite instability analysis; Hered Cancer Clin Pract 2004; 2(4): 176-84.
14. Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010; 42: 410-4.
15. Loveday C, Turnbull C, Ramsay E, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 2011; 43: 879-93.
16. Sieber OM, Segditsas S, Knudsen AL, et al. Disease severity and genetic pathways in attenuated familial adenomatous polyposis vary greatly but depend on the site of the germline mutation. Gut 2006; 55: 1440-8.
17. Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001; 68: 410-9.
18. Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet 2008; 40: 17-22.
19. Bodmer W, Bonilla C. Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet 2008; 40: 695-701.
20. Tomlinson IP, Webb E, Carvajal-Carmona L, et al. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet 2008; 40: 623-30.
21. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447: 1087-93.
22. Osorio A, Milne RL, Pita G, et al. Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). Br J Cancer 2009; 101: 2048-54.
23. Antoniou AC, Sinilnikova OM, McGuffog L, et al. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 2009; 18: 4442-56.
24. Seal S, Thompson D, Renwick A, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006; 38: 1239-41.
25. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007; 39: 165-7.
26. Renwick A, Thompson D, Seal S, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006; 38: 873-5.
27. Pharoah PD, Antoniou AC, Easton DF, Ponder BA. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008; 358: 2796-803.
28. Kaye J. The regulation of direct-to-consumer genetic tests. Hum Mol Genet 2008; 17: R180-3.
29. Gail MH. Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst 2008; 100: 1037-41.
30. Gardner EJ, Richards RC. Multiple cutaneous and subcutaneous lesions occurring simultaneously with hereditary polyposis and osteomatosis. Am J Hum Genet 1953; 5: 139-47.
31. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol 2006; 101: 385-98.
32. Eccles DM, van der LR, Breukel C, et al. Hereditary desmoid disease due to a frameshift mutation at codon 1924 of the APC gene. Am J Hum Genet 1996; 59: 1193-201.
33. Chapman PD, Church W, Burn J, Gunn A. Congenital hypertrophy of retinal pigment epithelium: a sign of familial adenomatous polyposis. BMJ 1989; 298: 353-4.
34. Vasen HF, Moslein G, Alonso A, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008; 57: 704-13.
35. Bunyan DJ, Eccles DM, Sillibourne J, et al. Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. Br J Cancer 2004; 91: 1155-9.
36. Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G: C-->T: a mutations in colorectal tumors. Nat Genet 2002; 30: 227-32.
37. Sampson JR, Dolwani S, Jones S, et al. Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. Lancet 2003; 362: 39-41.
38. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009; 11: 42-65.
39. Nystrom-Lahti M, Wu Y, Moisio AL, et al. DNA mismatch repair gene mutations in 55 kindreds with verified or putative hereditary non-polyposis colorectal cancer. Hum Mol Genet 1996; 5: 763-9.
40. Liu B, Parsons R, Papadopoulos N, et al. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med 1996; 2: 169-74.
41. Vasen HF, Moslein G, Alonso A, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007; 44: 353-62.
42. Choi YH, Cotterchio M, McKeown-Eyssen G, et al. Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario. Hereditary Cancer in Clinical Practice 2009; 7: 14.
43. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 2009; 76: 1-18.
44. Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008; 123: 444-9.
45. Quehenberger F, Vasen HF, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet 2005; 42: 491-6.
46. Vasen HF. Review article: The Lynch syndrome (hereditary nonpolyposis colorectal cancer). Aliment Pharmacol Ther 2007; 26(Suppl 2): 113-26.
47. Li FP, Fraumeni JF, Jr. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 1969; 43: 1365-73.
48. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-8.
49. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-30.
50. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-89.
51. Plon SE, Eccles DM, Easton D, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Human Mutation 2008; 29: 1282-91.
52. Wu JS, Paul P, McGannon EA, Church JM. APC genotype, polyp number, and surgical options in familial adenomatous polyposis. Ann Surg 1998; 227: 57-62.
53. Eccles D, Simmonds P, Goddard J, et al. Familial breast cancer: an investigation into the outcome of treatment for early stage disease. Familial Cancer 2001; 1: 72.
54. Burn J, Chapman PD, Bishop DT, Mathers J. Diet and cancer prevention: the concerted action polyp prevention (CAPP) studies. Proc Nutr Soc 1998; 57: 183-6.
55. Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002; 346: 1054-9.
56. Phillips RK, Wallace MH, Lynch PM, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002; 50: 857-60.
57. Jarvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000; 118: 829-34.
58. Mecklin JP, Aarnio M, Laara E, et al. Development of colorectal tumors in colonoscopic surveillance in Lynch syndrome. Gastroenterology 2007; 133: 1093-8.
59. Stoffel EM, Turgeon DK, Stockwell DH, et al. Missed adenomas during colonoscopic surveillance in individuals with Lynch Syndrome (hereditary nonpolyposis colorectal cancer). Cancer Prev Res (Phila) 2008; 1: 470-5.
60. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002; 288: 321-33.
61. Utian WH, Archer DF, Bachmann GA, et al. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008; 15: 584-602.
62. Renkonen-Sinisalo L, Butzow R, Leminen A, Lehtovirta P, Mecklin JP, Jarvinen HJ. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 2007; 120: 821-4.
63. Burn J, Bishop DT, Mecklin JP, et al. Effect of Aspirin or resistant starch on colorectal neoplasia in the lynch syndrome. N Engl J Med 2008; 359: 2567-78.
64. Burn J, Bishop DT, Chapman PD, et al. A randomized placebocontrolled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) 2011; 4: 655-65.
65. Smith A, Moran A, Boyd MC, et al. Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. J Med Genet 2007; 44: 10-15.
66. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005; 11: 5175-80.
67. Evans DGR, Baildam AD, Anderson E, et al. Risk reducing mastectomy: outcomes in 10 European centres. J Med Genet 2009; 46: 254-8.
68. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 159-64.
69. Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 2010; 28: 222-31.
70. Grindedal EM, Renkonen-Sinisalo L, Vasen H, et al. Survival in women with MMR mutations and ovarian cancer; a multicentre study in Lynch Syndrome kindreds. J Med Genet 2010; 47: 99 e102.
71. Evans DG, Young K, Bulman M, Shenton A, Wallace A, Lalloo F. Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families. Clin Genet 2008; 73: 338-45.
72. Stirling D, Evans DG, Pichert G, et al. Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system. J Clin Oncol 2005; 23: 5588-96.
73. Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res 2007; 5: 35-44.
74. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 1609-15.
75. Rebbeck TR, Friebel T, Wagner T, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005; 23: 7804-10.
76. Eisen A, Lubinski J, Gronwald J, et al; the Hereditary Breast Cancer Clinical Study Group. Hormone therapy and the risk of breast cancer in brca1 mutation carriers. J Natl Cancer Inst 2008; 100: 1361-7.
77. Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with brca1/2 mutations: a decision analysis. J Clin Oncol 2004; 22: 1045-54.
78. Nelson HD, Fu R, Griffin JC, Nygren P, Smith ME, Humphrey L. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med 2009; 151: 703-226.
79. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007; 99: 272-82.
80. Evans D, Lalloo F, Shenton A, Boggis C, Howell A: Uptake of screening and prevention in women at very high risk of breast cancer. Lancet 2001; 358: 889-890.
81. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63: 6221-8.
82. Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010; 28: 375-9.
83. Koopman M, Kortman GA, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009; 100: 266-73.
84. Koopman M, Venderbosch S, Nagtegaal ID, van Krieken JH, Punt CJ. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? Eur J Cancer 2009; 45: 1935-49.
85. Martin SA, McCarthy A, Barber LJ, et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med 2009; 1: 323-37.
86. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
87. Ratnam K, Low JA. Current development of clinical inhibitors of poly (ADP-ribose) polymerase in oncology. Clin Cancer Res 2007; 13: 1383-8.